Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes

Early in the SARS-CoV-2 pandemic, convalescent plasma (CP) therapy was proposed as a treatment for severely ill patients. We conducted a CP treatment protocol under the Mayo Clinic Extended Access Program at University Hospital Brooklyn (UHB). Potential donors were screened with a lateral flow assay...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendoza, Rachelle P., Fyke, William, Daniel, David, Gabutan, Elmer, Das, Ballabh, Bajaj, Harsha, Easy, Maxine, Vasileva, Ana, Colbourn, Robert, Alawad, Mouyed, Dehghani, Amir, Lin, Bo, Emechebe, Dokpe, Patel, Purvi, Jabbar, Absia, Nikolov, Dimitar B., Giovaniello, Dominick, Kang, Steven, Tatem, Luis, Bromberg, Kenneth, Augenbraun, Michael, Premsrirut, Prem, Libien, Jenny, Norin, Allen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Inc. on behalf of American Society for Histocompatibility and Immunogenetics. 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885628/
https://www.ncbi.nlm.nih.gov/pubmed/33640208
http://dx.doi.org/10.1016/j.humimm.2021.02.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885628/
https://www.ncbi.nlm.nih.gov/pubmed/33640208
http://dx.doi.org/10.1016/j.humimm.2021.02.007

Ejemplares similares